736 related articles for article (PubMed ID: 28202353)
21. Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy.
Shaked Y; Pham E; Hariharan S; Magidey K; Beyar-Katz O; Xu P; Man S; Wu FT; Miller V; Andrews D; Kerbel RS
Cancer Res; 2016 Oct; 76(20):5983-5993. PubMed ID: 27569209
[TBL] [Abstract][Full Text] [Related]
22. Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy.
Paez-Ribes M; Man S; Xu P; Kerbel RS
Clin Cancer Res; 2015 Dec; 21(24):5488-98. PubMed ID: 26169967
[TBL] [Abstract][Full Text] [Related]
23. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.
Shaked Y; Emmenegger U; Man S; Cervi D; Bertolini F; Ben-David Y; Kerbel RS
Blood; 2005 Nov; 106(9):3058-61. PubMed ID: 15998832
[TBL] [Abstract][Full Text] [Related]
24. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
[TBL] [Abstract][Full Text] [Related]
25. Metronomic chemotherapy and nanocarrier platforms.
Abu Lila AS; Ishida T
Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
[TBL] [Abstract][Full Text] [Related]
26. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
Naganuma Y; Choijamts B; Shirota K; Nakajima K; Ogata S; Miyamoto S; Kawarabayashi T; Emoto M
Cancer Sci; 2011 Aug; 102(8):1545-52. PubMed ID: 21631643
[TBL] [Abstract][Full Text] [Related]
27. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Man S; Munoz R; Kerbel RS
Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
[TBL] [Abstract][Full Text] [Related]
28. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
[TBL] [Abstract][Full Text] [Related]
29. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
Chow A; Wong A; Francia G; Man S; Kerbel RS; Emmenegger U
Invest New Drugs; 2014 Feb; 32(1):47-59. PubMed ID: 23728939
[TBL] [Abstract][Full Text] [Related]
30. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Tang TC; Man S; Lee CR; Xu P; Kerbel RS
Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
Ferdous T; Harada K; Kin T; Harada T; Ueyama Y
Int J Oncol; 2013 Jul; 43(1):271-9. PubMed ID: 23695365
[TBL] [Abstract][Full Text] [Related]
32. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
[TBL] [Abstract][Full Text] [Related]
33. Metronomic chemotherapy in metastatic colorectal cancer.
Woo IS; Jung YH
Cancer Lett; 2017 Aug; 400():319-324. PubMed ID: 28274890
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.
Bocci G; Kerbel RS
Nat Rev Clin Oncol; 2016 Nov; 13(11):659-673. PubMed ID: 27184418
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
37. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Francia G; Shaked Y; Hashimoto K; Sun J; Yin M; Cesta C; Xu P; Man S; Hackl C; Stewart J; Uhlik M; Dantzig AH; Foster FS; Kerbel RS
Mol Cancer Ther; 2012 Mar; 11(3):680-9. PubMed ID: 22188817
[TBL] [Abstract][Full Text] [Related]
38. Reappraising antiangiogenic therapy for breast cancer.
Kerbel RS
Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
[TBL] [Abstract][Full Text] [Related]
39. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
Qin RS; Zhang ZH; Zhu NP; Chen F; Guo Q; Hu HW; Fu SZ; Liu SS; Chen Y; Fan J; Han YW
BMC Cancer; 2018 Oct; 18(1):967. PubMed ID: 30305062
[TBL] [Abstract][Full Text] [Related]
40. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
